Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...

Bioprocessing offers key market opportunities in optimizing upstream and downstream processes to enhance yield and purity of pharmaceuticals, biofuels, and specialty chemicals. Innovations in cell ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

The two main fixation formats used by researchers are formalin fixation followed by paraffin embedding (FFPE) or snap-frozen in liquid nitrogen (referred to as Fresh Frozen or FF). There is less of a ...